Amneal Pharmaceuticals layoffs, on the record
Every job cut, severance charge and restructuring Amneal Pharmaceuticals reported in its annual reports, 2023 to 2025, quoted from the filings.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 7,700 | December 31, 2023 |
Job cuts, severance and restructuring
Our summaryThe filing reports restructuring and other charges of $1.7 million in 2023 in the consolidated results, with no workforce reduction described.
Word for word“Restructuring and other charges 1,749 1,421 328 23.1% Change in fair value of contingent consideration (14,497) 731 (15,228) nm Insurance recoveries for property losses and associated expenses — (1,911) 1,911 (100.0)% Charges related to legal matters, net 1,824 269,930 (268,106) (99.3)% Other operating income (1,138) (3,960) 2,822 (71.3)% Operating income (loss) 204,374 (94,928) 299,302 nm Total other expense, net (244,644) (153,199) (91,445) 59.7% Loss before income taxes (40,270) (248,127) 207,857 (83.8)% Provision for income taxes 8,452 6,662 1,790 26.9% Net loss $ (48,722) $ (254,789) $ 206,067 (80.9)% nm - not meaningful Net Revenue Net revenue for the year ended December 31, 2023 increased 8.2% from the prior year primarily due to: • Growth in our Generics segment of $39.3 million primarily due to new generics products launched in 2023 and 2022, which included biosimilars that contributed $62.6 million and new generic products that contributed $47.4 million, partially offset by price erosion.” 10-K for 2023
| Fiscal year ended | Restructuring charges |
|---|---|
| 2016-12-31 | $0 |
| 2017-12-31 | $0 |
| 2018-12-31 | $56.4 million |
| 2019-12-31 | $34.3 million |
| 2020-12-31 | $2.4 million |
| 2021-12-31 | $1.9 million |
| 2022-12-31 | $1.4 million |
| 2023-12-31 | $1.7 million |
| 2024-12-31 | $2.4 million |
| 2025-12-31 | $4.2 million |
Amneal Pharmaceuticals filed 2 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Amneal Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-27. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.